Bluebird bio Inc


BLUE

Price

7.54


Change

0.56


High

NA


Low

NA


Avg Volume

9,468,889


PE Ratio

-0.68


52 Week High

17.85


52 Week Low

2.87



Profile

bluebird bio, Inc., based in Cambridge, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders and cancer. The company's only - in the European Union - approved drug is betibeglogene autotemcel , which treats transfusion-dependent beta thalassemia , a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. The company has been criticized for the $1.8 million cost of the drug, which is the second most expensive drug in the world.


Top Streaming News


Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.

Data provided by IEX Cloud

About

Copyright © 2020 Finaza.IO. All Rights Reserved.